Circular ssDNA boosts TALEN editing efficiency
CMN Briefs
May. 13, 2025
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Revvity
Company Type: CRO
Main focus: Improved diagnostic tools
Company stage: Actively providing services
Diseases: N/A
Genome-editing tool: Pin-Point (base editing)
Funding stage: IPO (NYSE: RVTY)
Location: Waltham, MA, USA
Website: https://www.revvity.com
Pipeline: N/A
Partners: Astrazeneca
Revvity is a CRO providing a broad range of services within diagnostics. It offers solutions for genomics. protein and cell analysis. The services are provided within the following disease areas: infectious diseases, autoimmunity, endocrinology, allergy, cancer, and neurodegeneration. In May 2023, the company signed an agreement with Astrazeneca, which allows Astrazeneca to license Revvity's Pin-Point base-editing technology.
